Tofacitinib or Baricitinib ( DrugBank: Tofacitinib, Baricitinib )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04449224 (ClinicalTrials.gov) | April 27, 2020 | 7/6/2020 | Comparative Effectiveness of Targeted Therapy in RA Patients | Comparative Effectiveness of Biologic Disease-modifying Antirheumatic Drugs and Small Molecular Inhibitors in Patients With Moderate to Severe RA: Prospective Observational Study | Rheumatoid Arthritis | Drug: Adalimuab, Etanercept, Tocilizumab, or Abatacept;Drug: Tofacitinib or Baricitinib | Hanyang University | Ministry of Health, Republic of Korea | Recruiting | 19 Years | N/A | All | 506 | Korea, Republic of |